What happened with SLQT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
SelectQuote, Inc. serves people choosing insurance coverage and patients who need regular medication for chronic conditions. Its SelectRx business fills prescriptions through company-owned pharmacies and packages medications for patients. Prescription-drug sales generate substantially all pharmacy revenue, paid mainly through third-party reimbursement, including Medicare Part D and Medicaid. Pharmacy is now the company’s largest revenue source. These services are available only to certain Medicare Advantage patients managing multiple chronic conditions, and the pharmacy relies heavily on insurance-sales leads to find customers.
For insurance, SelectQuote attracts prospective buyers through advertising and partners, then uses software to route them to licensed agents who help choose coverage from insurers. Medicare Advantage dominates its Senior business; it also sells life insurance. Insurers pay SelectQuote commissions on sales and, where applicable, renewals. Consumers do not pay it directly for this service, and SelectQuote neither issues policies nor bears the insurance risk.
Earnings depend on acquiring suitable leads, converting them into sales, keeping policies and pharmacy members active, and the commission and drug-reimbursement terms negotiated with partners. UnitedHealthcare, Humana and Aetna together supply most revenue across Senior and Healthcare Services, with UnitedHealthcare the largest. Medicare’s annual enrollment season drives both insurance sales and new pharmacy enrollments. SelectQuote must maintain company and agent insurance licenses and follow Medicare marketing and enrollment rules; its pharmacies also operate under federal and state healthcare requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond this list, watch UnitedHealthcare and Aetna: they supplied 39% and 12% of SelectQuote’s fiscal 2026 revenue across insurance distribution and healthcare services, even as pharmacy now supplies over half its revenue.
eHealth competes with SelectQuote to help seniors enroll in Medicare plans; insurers pay both companies commissions, and neither bears the risk of insurance claims. With Medicare supplying about 96% of eHealth’s 2025 revenue, its Medicare enrollment results are a focused read on competition for SelectQuote’s senior customers.
Humana is both a payer and a rival to SelectQuote: it paid for insurance distribution and healthcare services that generated 13% of SelectQuote’s fiscal 2026 revenue. Humana sells health insurance and provides care through CenterWell, whose pharmacy business competes with SelectQuote’s SelectRx prescription services.
Ethos Technologies Inc. competes with SelectQuote to sell life insurance; both earn commissions from partner insurers when policies are first sold and renewed, while those insurers bear the insurance risk.
Fed Interest Rate Decision
SelectQuote’s debt means Fed rate decisions matter because higher interest rates can raise borrowing costs on debt that reprices, leaving less cash for its insurance-sales and pharmacy operations, while lower rates can ease that burden.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could raise interest expense on debt that reprices, reducing the cash SelectQuote has available to fund operations and investment.
If it comes in below expectations
Lower rates could ease interest expense on debt that reprices, leaving SelectQuote more cash for operations and investment.
Ethos Technologies Inc. earningsLIFE
Ethos earns insurer-paid commissions on life policies, as SelectQuote does, so its report will show how strongly the two compete for life-insurance customers.
Read Ethos’s life-policy sales alongside its commission revenue. Growth in both would show its channel expanding and tougher competition for SelectQuote’s life customers; weakness in both would point to less competitive pressure. Ethos’s growth alone would not prove that it took customers from SelectQuote.
SelectQuote, Inc. earningsThis company
SelectQuote earns commissions from insurers and pharmacy revenue from SelectRx, and this report will show whether its Medicare sales channel is holding its value as the pharmacy business expands.
Read estimated lifetime commissions per approved Medicare Advantage policy—the commissions expected over a policy’s life—alongside the number of approved policies, then check SelectRx’s active members and prescriptions shipped per business day. If policy value and sales hold up while both pharmacy measures rise, both engines are contributing; if policy value or sales weaken and growth comes mainly from pharmacy, revenue is shifting toward pharmacy as the insurance channel loses ground.
eHealth, Inc. earningsEHTH
eHealth and SelectQuote both enroll seniors in Medicare plans for insurer-paid commissions, so eHealth’s report will show whether competition for senior customers is intensifying.
Watch eHealth’s Medicare enrollment and related revenue. If both grow, this direct rival is expanding and competition for SelectQuote’s senior customers is stronger; if both weaken, there is less evidence of that pressure. eHealth’s growth alone does not prove it took customers from SelectQuote.
Humana Inc. earningsHUM
Humana is both a major insurance payer to SelectQuote and a pharmacy rival to SelectRx, so its report offers a read on both connections.
Read Humana’s Medicare business alongside CenterWell pharmacy activity, and compare the pharmacy picture with SelectQuote’s SelectRx members and prescriptions shipped per business day. Growth in both Humana businesses would show this major payer and pharmacy rival gaining scale; weakness would mean less evidence of that expansion, but would not show how Humana’s actual commissions to SelectQuote changed.
